Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus

Grund, Sebastian; Adams, Ortwin; Wählisch, Stephanie; Schweiger, Brunhilde

doi:10.1016/j.jviromet.2010.11.024

Cited by 57 publications

(44 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The negated occurrence of Xulike symptoms post-vaccination might give some (weak) evidence for successful protection. One explanation could be the method itself: Several authors have shown that the hemagglutination inhibition test is less sensitive compared to tests that detect virus-neutralizing antibodies [36,37]. However, Broeders et al [28] have tested post-vaccination sera of renal transplant recipients and hemodialysis patients for the presence of neutralizing antibodies against the pandemic H1N1 strain and found similar to this study that in these patients, the vaccine is of limited eYcacy [28].…”

Section: Discussionsupporting

confidence: 56%

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Ott

Sauerbrei

Lange

et al. 2012

Med Microbiol Immunol

View full text Add to dashboard Cite

In the present study, antibody response to seasonal influenza vaccination and to the adjuvanted one-shot influenza A H1N1 vaccine (Pandemrix(®)) was investigated in 57 hemodialysis (HD) patients and 48 renal transplant (RT) recipients. Specific antibodies were measured by hemagglutination inhibition (HI) test using a pandemic H1N1 strain and a seasonal H3N2 virus. HI titers of ≥1:40 were considered as protective. Hemodialysis patients showed seroprotection against pandemic H1N1 in 35.1%, against seasonal influenza in 36.8% and against both in 14.0%. In comparison, renal transplant recipients developed protective antibody titers against the pandemic H1N1 virus in 47.9%, against the seasonal H3N2 strain in 31.3% and against both in 18.8%. HD patients and renal transplant recipients younger than 60 years developed protective antibody response to the pandemic influenza H1N1 vaccine in 50.0% of the HD patients and 55.2% of the RT recipients and against seasonal influenza in 45.0/20.7% (HD/RT) of the cases. Patients aged ≥60 years showed seroprotection against pandemic influenza in 27.0/36.8% (HD/RT) and against seasonal influenza in 32.4/47.4% (HD/RT). Side effects were reported in only four patients. In hemodialysis patients and renal transplant recipients, vaccination against pandemic H1N1 and seasonal influenza is well tolerated. However, more than a half of these patients did not develop seroprotective antibody levels. Thus, new vaccines and altered vaccination regimes are likely necessary to achieve relevant antibody levels in these patient groups.

show abstract

Section: Discussionsupporting

confidence: 56%

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Ott

Sauerbrei

Lange

et al. 2012

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

“…HI and microneutralization titers were determined using routine methods, as described previously (34)(35)(36)(37). The microneutralization assay has been shown to have better sensitivity in detecting serum antibodies than HI assays, and findings correlate with protection against seasonal influenza (38)(39)(40). However, HI assays offer several advantages, i.e., they are relatively simple and inexpensive to perform and are widely used around the world, allowing easier comparisons and perhaps standardization (41).…”

Section: Methodsmentioning

confidence: 99%

Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans

Epps

Tumpey

Pearce

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

Both preexisting immunity to influenza and age have been shown to be correlates of influenza vaccine responses. Frailty, an indicator of functional impairment in older adults, was also shown in one study to predict lower influenza vaccine responses among nonveterans. In the current study, we aimed to determine the associations between frailty, preexisting immunity, and immune responses to influenza vaccine among older veterans. We studied 117 subjects (age range, 62 to 95 years [median age, 81 years]), divided into three cohorts based on the Fried frailty test, i.e., nonfrail (NF) (n ϭ 23 [median age, 68 years]), prefrail (n ϭ 50 [median age, 80 years]), and frail (n ϭ 44 [median age, 82 years]), during the 2010-2011 and 2011-2012 influenza seasons. Subjects received the seasonal trivalent inactivated influenza vaccine, and baseline and postvaccination samples were obtained. Anti-influenza humoral immunity, as measured by hemagglutination inhibition (HI) and microneutralization assays, was measured for influenza B, A(H1N1)pdm09, and A(H3N2) viruses. Postvaccination titers were not different between frail and NF subjects overall in this older subset of veterans. However, preexisting HI titers were strongly correlated with postvaccination titers among all functional status groups. When microneutralization titers were compared, the association between preexisting immunity and vaccine responses varied by frailty status, with the strongest correlation being observed for the NF group. In conclusion, preexisting immunity rather than frailty appeared to predict postvaccination titers in this older veteran cohort.

show abstract

“…In the hemagglutinin inhibition assays (HIAs), a serum dilution of 1:40 is considered protective whereas comparable values were found for an ELISA-based and a colorimetric microneutralization assay; however, these values are not applicable to our assay [13], in particular as it was also shown that ELISA values and HIA values do not correlate, not even within the same subtypes [14]. Moreover, because the majority of heterosubtypic antibodies was found to bind a conserved epitope in the stem of the HA protein and did not interfere with hemagglutination [15,16], they would not be detected by HIAs.…”

Section: Discussionmentioning

confidence: 80%

Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus

Kohler¹,

Scherrer²,

Zagordi³

et al. 2014

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background. The effectiveness of trivalent influenza vaccination has been confirmed in several studies. To date, it is not known whether repeated exposure and vaccination to influenza promote production of cross-reactive antibodies. Furthermore, how strains encountered earlier in life imprint the immune response is currently poorly understood.Methods. To determine the prevalence for human homo-and heterosubtypic antibody responses, we scrutinized serum samples from 305 healthy volunteers for hemagglutinin-binding and -neutralizing antibodies against several strains and subtypes of influenza A. Statistical analyses were then performed to establish the association of measured values with potential predictors.Results. It was found that vaccination not only promoted higher binding and neutralizing antibody titers to homosubtypic influenza isolates but also increased heterosubtypic human immune responses. Both binding and neutralizing antibody titers in relation with age of the donors mirrored the course of the different influenza strain circulation during the last century. Advanced age appeared to be of advantage for both binding and neutralizing titers to most subtypes. In contrast, the first virus subtype encountered was found to imprint to some degree subsequent antibody responses. Antibodies to recent strains, however, primarily seemed to be promoted by vaccination.Conclusions. We provide evidence that vaccinations stimulate both homo-and heterosubtypic immune responses in young and middle-aged as well as more senior individuals. Our analyses suggest that influenza vaccinations not only prevent infection against currently circulating strains but can also stimulate broader humoral immune responses that potentially attenuate infections with zoonotic or antigenically shifted strains.

show abstract

Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus

Cited by 57 publications

References 13 publications

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans

Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus

Contact Info

Product

Resources

About